Split History
ETFs Holding PCSA »    PCSA Historical Stock Prices »



Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Processa Pharmaceuticals is a biopharmaceutical company focused on utilizing the Processa Regulatory Science Approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. Co.'s pipeline consists of three oncology drugs: NGC Capecitabine, which is an orally administered irreversible inhibitor of the enzyme dihydropyrimidine dehydrogenase; NGC-Gemcitabine, which is a cytidine analog similar to gemcitabine (Gemzar®), but different enough in chemical structure that some patients are more likely to respond to PCS3117 than gemcitabine; and NGC-Irinotecan, which is an analog of SN38, the active metabolite of irinotecan; and two non-oncology drugs: PCS12852 and PCS499. According to our PCSA split history records, Processa Pharmaceuticals has had 1 split.
PCSA split history picture
Processa Pharmaceuticals (PCSA) has 1 split in our PCSA split history database. The split for PCSA took place on January 22, 2024. This was a 1 for 20 reverse split, meaning for each 20 shares of PCSA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.

When a company such as Processa Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the PCSA split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Processa Pharmaceuticals shares, starting with a $10,000 purchase of PCSA, presented on a split-history-adjusted basis factoring in the complete PCSA split history. PCSA split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/02/2014
End date: 04/30/2024
Start price/share: $50.00
End price/share: $2.18
Dividends collected/share: $0.00
Total return: -95.64%
Average Annual Total Return: -26.89%
Starting investment: $10,000.00
Ending investment: $435.91
Years: 10.00
Date Ratio
01/22/20241 for 20
PCSA is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

PDCO Split History
PDSB Split History
PFE Split History
PHIO Split History
PHMD Split History
PIP Split History
PIRS Split History
PKI Split History
PLI Split History
PLUR Split History

Also explore: PCSA shares outstanding history

Email EnvelopeFree PCSA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Gaucho Group Holdings, Inc. (VINO)
STRATA Skin Sciences, Inc. (SSKN)
Society Pass Inc. (SOPA)
Recon Technology, Ltd. (RCON)
iSun, Inc. (ISUN)
Avenue Therapeutics, Inc. (ATXI)
Bakkt Holdings, Inc. (BKKT)
Applied DNA Sciences, Inc. (APDN)
Cidara Therapeutics, Inc. (CDTX)
Smart for Life, Inc. (SMFL)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

PCSA Insider Buying

PCSA Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.